| pubmed-article:9873610 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9873610 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:9873610 | lifeskim:mentions | umls-concept:C2717971 | lld:lifeskim |
| pubmed-article:9873610 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9873610 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:9873610 | lifeskim:mentions | umls-concept:C1707271 | lld:lifeskim |
| pubmed-article:9873610 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:9873610 | pubmed:dateCreated | 1999-2-2 | lld:pubmed |
| pubmed-article:9873610 | pubmed:abstractText | Replacement of the C-terminal carboxylic acid functionality of peptide inhibitors of hepatitis C virus (HCV) NS3 protease (complexed with NS4A peptide cofactor) by activated carbonyl groups does not produce any substantial increase in potency. These latter inhibitors also inhibit a variety of other serine and cysteine proteases whereas the carboxylic acids are specific. Norvaline was identified as a chemically stable replacement for the P1 residue of Ac-DDIVPC-OH which was also compatible with activated carbonyl functionalities. | lld:pubmed |
| pubmed-article:9873610 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9873610 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873610 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9873610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873610 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9873610 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9873610 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:HalmosTT | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:BaileyMM | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:PoupartM AMA | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:PoirierMM | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:RancourtJJ | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:WernicDD | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:ThibeaultDD | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:LamarreDD | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:MauriceRR | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:GouletSS | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:DézielRR | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:Llinàs-Brunet... | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:FazalGG | lld:pubmed |
| pubmed-article:9873610 | pubmed:author | pubmed-author:GorysVV | lld:pubmed |
| pubmed-article:9873610 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9873610 | pubmed:day | 6 | lld:pubmed |
| pubmed-article:9873610 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:9873610 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9873610 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9873610 | pubmed:pagination | 2719-24 | lld:pubmed |
| pubmed-article:9873610 | pubmed:dateRevised | 2001-11-2 | lld:pubmed |
| pubmed-article:9873610 | pubmed:meshHeading | pubmed-meshheading:9873610-... | lld:pubmed |
| pubmed-article:9873610 | pubmed:meshHeading | pubmed-meshheading:9873610-... | lld:pubmed |
| pubmed-article:9873610 | pubmed:meshHeading | pubmed-meshheading:9873610-... | lld:pubmed |
| pubmed-article:9873610 | pubmed:meshHeading | pubmed-meshheading:9873610-... | lld:pubmed |
| pubmed-article:9873610 | pubmed:meshHeading | pubmed-meshheading:9873610-... | lld:pubmed |
| pubmed-article:9873610 | pubmed:meshHeading | pubmed-meshheading:9873610-... | lld:pubmed |
| pubmed-article:9873610 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9873610 | pubmed:articleTitle | Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. | lld:pubmed |
| pubmed-article:9873610 | pubmed:affiliation | Boehringer Ingelheim (Canada) Ltd, Bio-Méga Research Division, Laval, Québec, Canada. | lld:pubmed |
| pubmed-article:9873610 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:9873610 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9873610 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9873610 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9873610 | lld:pubmed |
